OTCMKTS:NBIO

Nascent Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy NBIO

*Your capital is at risk

$0.0004

+0 (+0%)

At Close: Jun 03, 2026

Nascent Biotech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 42.59M and sold 14.33M NBIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	42.59M shares
● Sell	14.33M shares
84% Buy Activity Moderate Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 09, 2021 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	307 010 Value: $23.3K
Apr 09, 2021 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	307 010 Value: $23.3K
Mar 31, 2021 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	810 000 Value: $49.4K
Mar 31, 2021 Buy	Common Stock J-Other	Carrick Sean Insider	Other	1 620 000 Value: $98.8K
Mar 31, 2021 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	83 334 Value: $6K
Mar 31, 2021 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	810 000 Value: $49.4K
Mar 31, 2021 Buy	Common Stock J-Other	Carrick Sean Insider	Other	1 620 000 Value: $98.8K
Mar 31, 2021 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	83 334 Value: $6K
Mar 26, 2021 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	1 000 000 Value: $60.0K
Mar 26, 2021 Buy	Common Stock J-Other	Carrick Sean Insider	Other	1 250 000 Value: $75.0K
Mar 26, 2021 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	1 000 000 Value: $60.0K
Mar 26, 2021 Buy	Common Stock J-Other	Carrick Sean Insider	Other	1 250 000 Value: $75.0K
Dec 31, 2020 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	108 460 Value: $5K
Dec 31, 2020 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	1 442 000 Value: $66.5K
Dec 31, 2020 Buy	Common Stock J-Other	Carrick Sean Insider	Other	2 884 000 Value: $133.0K
Dec 31, 2020 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	1 442 000 Value: $66.5K
Dec 31, 2020 Buy	Common Stock J-Other	Carrick Sean Insider	Other	2 884 000 Value: $133.0K
Nov 20, 2020 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	350 000 Value: $17.5K
Nov 20, 2020 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	350 000 Value: $17.5K
Sep 30, 2020 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	71 430 Value: $5K
Sep 30, 2020 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	127 970 Value: $9K
Sep 30, 2020 Buy	Common Stock J-Other	Carrick Sean Insider	Other	218 715 Value: $21.9K
Sep 30, 2020 Buy	Common Stock J-Other	Karas Douglas John Insider	Other	71 430 Value: $5K
Sep 30, 2020 Buy	Common Stock J-Other	Holden Lowell Thomas Insider	Other	127 970 Value: $9K
Sep 30, 2020 Buy	Common Stock J-Other	Carrick Sean Insider	Other	218 715 Value: $21.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NASCENT BIOTECH, INC.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platfo...

Read Full Profile Here